Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Joseph M. Custodio"'
Autor:
Pamela N. Munster, Andrew E. Greenstein, Gini F. Fleming, Erkut Borazanci, Manish R. Sharma, Joseph M. Custodio, Iulia Cristina Tudor, Hristina I. Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C. Sachdev
Publikováno v:
Clinical Cancer Research. 28:3214-3224
Purpose: Chemotherapy resistance remains a major problem in many solid tumors, including breast, ovarian, and pancreatic cancer. Glucocorticoids are one potential driver of chemotherapy resistance as they can mediate tumor progression via induction o
Autor:
Jasgit C. Sachdev, Andreas Grauer, Stacie Peacock Shepherd, Hristina I. Pashova, Iulia Cristina Tudor, Joseph M. Custodio, Manish R. Sharma, Erkut Borazanci, Gini F. Fleming, Andrew E. Greenstein, Pamela N. Munster
Supplementary Figure from Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2886d37fcff78b247cd03a79281bc5ec
https://doi.org/10.1158/1078-0432.22487951
https://doi.org/10.1158/1078-0432.22487951
Autor:
Jasgit C. Sachdev, Andreas Grauer, Stacie Peacock Shepherd, Hristina I. Pashova, Iulia Cristina Tudor, Joseph M. Custodio, Manish R. Sharma, Erkut Borazanci, Gini F. Fleming, Andrew E. Greenstein, Pamela N. Munster
Supplementary Data from Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61821b20827be2a56ab1e7f411cae314
https://doi.org/10.1158/1078-0432.22487954
https://doi.org/10.1158/1078-0432.22487954
Autor:
Jasgit C. Sachdev, Andreas Grauer, Stacie Peacock Shepherd, Hristina I. Pashova, Iulia Cristina Tudor, Joseph M. Custodio, Manish R. Sharma, Erkut Borazanci, Gini F. Fleming, Andrew E. Greenstein, Pamela N. Munster
Purpose:Chemotherapy resistance remains a major problem in many solid tumors, including breast, ovarian, and pancreatic cancer. Glucocorticoids are one potential driver of chemotherapy resistance as they can mediate tumor progression via induction of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49570b9f86aa2860793f871384777c84
https://doi.org/10.1158/1078-0432.c.6532622
https://doi.org/10.1158/1078-0432.c.6532622
Autor:
Diane Donegan, Rosario Pivonello, Antonio Stigliano, Pina Lardo, Tara Kearney, Emese Mezosi, Ezio Ghigo, Roberta Giordano, Cary N. Mariash, Richard A. Feelders, Kirsteen Donaldson, Borje Darpo, Joseph M. Custodio, Austin L. Hand, Andreas G. Moraitis
Publikováno v:
Endocrine Practice. 29:S75
Publikováno v:
Journal of Clinical Pharmacology
Relacorilant is a selective modulator of the glucocorticoid receptor in development for the treatment of several serious diseases. The widely used cocktail method was employed to assess relacorilant's effect on various cytochrome P450 (CYP) drug meta
Publikováno v:
Journal of the Endocrine Society. 6:A547-A547
Background Relacorilant is a highly selective glucocorticoid receptor (GR) modulator in development for the treatment of endogenous Cushing syndrome (CS). Unlike the FDA-approved GR antagonist mifepristone, relacorilant lacks affinity for the progest
Autor:
Catherine Creticos, Jean-Michel Molina, Hiba Graham, Jürgen K. Rockstroh, Ellen Koenig, Ya-Pei Liu, Joseph M. Custodio, Edwin DeJesus, Andrew T. A. Cheng, Erin Quirk, Peter Ruane, Gordon Crofoot, Godson Oguchi, Kristen Andreatta, Eric S. Daar, Hal Martin
Publikováno v:
The Lancet HIV. 5:e347-e356
Summary Background Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection,
Autor:
Marshall W. Fordyce, Timothy J. Wilkin, Lijie Zhong, Andrew K. Cheng, Joseph M. Custodio, Christian Callebaut, Joel E. Gallant, Mingjin Yan, Moupali Das, Gregory D Huhn, Pablo Tebas, Scott McCallister
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Background: HIV-infected, treatment-experienced adults with a history of prior resistance and regimen failure can be virologically suppressed but may require multitablet regimens associated
Background: HIV-infected, treatment-experienced adults with a history of prior resistance and regimen failure can be virologically suppressed but may require multitablet regimens associated
Autor:
Ami Dave, Marshall W. Fordyce, Srini Ramanathan, Brian P. Kearney, Kah Hiing J. Ling, Hui Wang, Joseph M. Custodio, Javier Szwarcberg, Xuelian Wei
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 72:281-288
Background Elvitegravir (EVG), a HIV integrase inhibitor, is metabolized primarily by CYP3A, and secondarily by UGT1A1/3; Efavirenz (EFV), a HIV non-nucleoside reverse transcriptase inhibitor, is metabolized by Cytochrome P450 (CYP) 2B6 and induces C